Marvipol S.A.
Marvipol Development S.A. engages in investing in and developing real estate projects in Poland. The company's property portfolio includes apartments and commercial premises. The company was founded in 1996 and is headquartered in Warsaw, Poland. Marvipol Development S.A. is a subsidiary of Ksiazek Holding Sp. z.o.o.
Marvipol S.A. (MVP) - Total Liabilities
Latest total liabilities as of September 2025: zł655.61 Million PLN
Based on the latest financial reports, Marvipol S.A. (MVP) has total liabilities worth zł655.61 Million PLN as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Marvipol S.A. - Total Liabilities Trend (2014–2024)
This chart illustrates how Marvipol S.A.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Marvipol S.A. Competitors by Total Liabilities
The table below lists competitors of Marvipol S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
LSL Pharma Group Inc.
V:LSL
|
Canada | CA$34.81 Million |
|
M&F Bancorp Inc
PINK:MFBP
|
USA | $374.46 Million |
|
MAGURO GROUP PUBLIC COMPANY LIMITED
BK:MAGURO
|
Thailand | ฿615.94 Million |
|
SJ Group Co. Ltd
KQ:306040
|
Korea | ₩96.06 Billion |
|
Dolphin Offshore Enterprises (India) Limited
NSE:DOLPHIN
|
India | ₹2.21 Billion |
|
Emperor International Holdings Limited
F:EM3A
|
Germany | €19.52 Billion |
|
GeneReach Biotechnology
TWO:4171
|
Taiwan | NT$285.79 Million |
|
Ozerden Plastik Sanayi
IS:OZRDN
|
Turkey | TL52.79 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Marvipol S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.90 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Marvipol S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Marvipol S.A. (2014–2024)
The table below shows the annual total liabilities of Marvipol S.A. from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł885.59 Million | +17.95% |
| 2023-12-31 | zł750.85 Million | +3.96% |
| 2022-12-31 | zł722.25 Million | -22.93% |
| 2021-12-31 | zł937.10 Million | +23.74% |
| 2020-12-31 | zł757.30 Million | -4.34% |
| 2019-12-31 | zł791.68 Million | +41.82% |
| 2018-12-31 | zł558.23 Million | +5.84% |
| 2017-12-31 | zł527.40 Million | +52.54% |
| 2016-12-31 | zł345.74 Million | -35.63% |
| 2015-12-31 | zł537.13 Million | -0.42% |
| 2014-12-31 | zł539.41 Million | -- |